

BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Three Months Ended September 30, 2013 and 2012
(unaudited)
(in millions, except per share and percentage data)

	Three Months Ended September 30,		
	2013	2012	Change
NET SALES	\$3,774	\$3,477	9%
COST OF SALES	1,828	1,667	10%
GROSS MARGIN	1,946	1,810	8%
<i>% of Net Sales</i>	<i>51.6%</i>	<i>52.1%</i>	<i>(0.5 pts)</i>
MARKETING AND ADMINISTRATIVE EXPENSES	984	743	32%
<i>% of Net Sales</i>	<i>26.1%</i>	<i>21.4%</i>	<i>4.7 pts</i>
RESEARCH AND DEVELOPMENT EXPENSES	290	290	0%
<i>% of Net Sales</i>	<i>7.7%</i>	<i>8.3%</i>	<i>(0.6 pts)</i>
NET INTEREST EXPENSE	45	25	80%
OTHER INCOME, NET	(55)	(14)	N/M
PRE-TAX INCOME	682	766	(11%)
INCOME TAX EXPENSE	138	183	(25%)
<i>% of Pre-Tax Income</i>	<i>20.2%</i>	<i>23.9%</i>	<i>(3.7 pts)</i>
NET INCOME	\$544	\$583	(7%)
BASIC EPS	\$1.00	\$1.07	(7%)
DILUTED EPS	\$0.99	\$1.06	(7%)
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Basic	543	548	
Diluted	549	552	
ADJUSTED PRE-TAX INCOME (excluding special items)	\$834 ^A	\$816 ^A	2%
ADJUSTED NET INCOME (excluding special items)	\$655 ^A	\$628 ^A	4%
ADJUSTED DILUTED EPS (excluding special items)	\$1.19 ^A	\$1.14 ^A	4%

^A Refer to page 8 for a description of the adjustments and a reconciliation to generally accepted accounting principles (GAAP) measures.

BAXTER INTERNATIONAL INC.
Note to Consolidated Statements of Income
Three Months Ended September 30, 2013 and 2012
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)

The company's GAAP results for the three months ended September 30, 2013 and 2012 included special items which impacted the GAAP measures as follows:

	Three Months Ended September 30,		
	2013	2012	Change
Gross Margin	\$1,946	\$1,810	8%
Gambro acquisition and integration items ¹	15	-	
Adjusted Gross Margin	\$1,961	\$1,810	8%
% of Net Sales	52.0%	52.1%	(0.1 pts)
Marketing and Administrative Expenses	\$984	\$743	32%
Gambro acquisition and integration items ¹	(33)	-	
Tax and legal reserves ²	(124)	-	
Adjusted Marketing and Administrative Expenses	\$827	\$743	11%
% of Net Sales	21.9%	21.4%	0.5 pts
Research and Development Expenses	\$290	\$290	0%
Business development items ³	(25)	(50)	
Adjusted Research and Development Expenses	\$265	\$240	10%
% of Net Sales	7.0%	6.9%	0.1 pts
Other Income, Net	\$(55)	\$(14)	N/M
Gambro acquisition and integration items ¹	(10)	-	
Tax and legal reserves ²	35	-	
Currency-related items ⁴	20	-	
Adjusted Other Income, Net	\$(10)	\$(14)	N/M
Pre-Tax Income	\$682	\$766	(11%)
Impact of special items	152	50	
Adjusted Pre-Tax Income	\$834	\$816	2%
Income Tax Expense	\$138	\$183	(25%)
Impact of special items	41	5	
Adjusted Income Tax Expense	\$179	\$188	(5%)
% of Adjusted Pre-Tax Income	21.5%	23.0%	(1.5 pts)
Net Income	\$544	\$583	(7%)
Impact of special items	111	45	
Adjusted Net Income	\$655	\$628	4%
Diluted EPS	\$0.99	\$1.06	(7%)
Impact of special items	0.20	0.08	
Adjusted Diluted EPS	\$1.19	\$1.14	4%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Diluted	549	552	

- ¹ Cost of sales, marketing and administrative expenses and other income, net in 2013 included total charges of \$58 million (\$53 million, or \$0.09 per diluted share, on an after-tax basis) principally related to the acquisition and integration of Gambro AB (Gambro), including post-acquisition restructuring activities.
- ² Marketing and administrative expenses in 2013 included charges totaling \$124 million (\$95 million, or \$0.17 per diluted share, on an after-tax basis) related to tax and legal reserves associated with VAT matters in Turkey and existing class-action and other related litigation, including litigation fees. Income tax expense in 2013 included a net benefit of \$6 million (\$0.01 per diluted share) related to uncertain tax positions in Switzerland and Turkey. Other income, net in 2013 included the offsetting impact of \$35 million (\$0.06 per diluted share) in noncontrolling interest for the VAT and tax items above associated with the company's non-wholly owned subsidiary in Turkey.
- ³ Research and development (R&D) expenses in 2013 included an R&D charge of \$25 million (\$17 million, or \$0.03 per diluted share, on an after-tax basis) related to the company's collaboration agreement with JW Holdings. R&D expenses in 2012 included an R&D charge of \$50 million (\$45 million, or \$0.08 per diluted share, on an after-tax basis) related to the company's licensing agreement with Onconova Therapeutics, Inc. (Onconova).
- ⁴ Other income, net in 2013 included a net gain of \$20 million (\$13 million, or \$0.02 per diluted share, on an after-tax basis) principally related to the company's derivative instruments used to hedge the anticipated foreign currency cash outflows for the Gambro acquisition.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

BAXTER INTERNATIONAL INC.
Consolidated Statements of Income
Nine Months Ended September 30, 2013 and 2012
(unaudited)
(in millions, except per share and percentage data)

	Nine Months Ended September 30,		
	2013	2012	Change
NET SALES	\$10,891	\$10,437	4%
COST OF SALES	5,250	5,041	4%
GROSS MARGIN	5,641	5,396	5%
<i>% of Net Sales</i>	<i>51.8%</i>	<i>51.7%</i>	<i>0.1 pts</i>
MARKETING AND ADMINISTRATIVE EXPENSES	2,617	2,284	15%
<i>% of Net Sales</i>	<i>24.0%</i>	<i>21.9%</i>	<i>2.1 pts</i>
RESEARCH AND DEVELOPMENT EXPENSES	809	865	(6%)
<i>% of Net Sales</i>	<i>7.4%</i>	<i>8.3%</i>	<i>(0.9 pts)</i>
NET INTEREST EXPENSE	87	65	34%
OTHER EXPENSE (INCOME), NET	10	(133)	N/M
PRE-TAX INCOME	2,118	2,315	(9%)
INCOME TAX EXPENSE	432	483	(11%)
<i>% of Pre-Tax Income</i>	<i>20.4%</i>	<i>20.9%</i>	<i>(0.5 pts)</i>
NET INCOME	\$1,686	\$1,832	(8%)
BASIC EPS	\$3.10	\$3.32	(7%)
DILUTED EPS	\$3.06	\$3.29	(7%)
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Basic	543	552	
Diluted	550	556	
ADJUSTED PRE-TAX INCOME (excluding special items)	\$2,391 ^A	\$2,329 ^A	3%
ADJUSTED NET INCOME (excluding special items)	\$1,875 ^A	\$1,816 ^A	3%
ADJUSTED DILUTED EPS (excluding special items)	\$3.41 ^A	\$3.27 ^A	4%

^A Refer to page 10 for a description of the adjustments and a reconciliation to GAAP measures.

BAXTER INTERNATIONAL INC.
Note to Consolidated Statements of Income
Nine Months Ended September 30, 2013 and 2012
Description of Adjustments and Reconciliation of GAAP to Non-GAAP Measures
(unaudited)
(in millions, except per share and percentage data)

The company's GAAP results for the nine months ended September 30, 2013 and 2012 included special items which impacted the GAAP measures as follows:

	Nine Months Ended September 30,		Change
	2013	2012	
Gross Margin	\$5,641	\$5,396	5%
Gambro acquisition and integration items ¹	15	-	
Currency-related items ²	1	-	
Business optimization items ³	(20)	-	
Business development items ⁵	-	6	
Reserve adjustments ⁶	-	(23)	
Adjusted Gross Margin	\$5,637	\$5,379	5%
% of Net Sales	51.8%	51.5%	0.3 pts
Marketing and Administrative Expenses	\$2,617	\$2,284	15%
Gambro acquisition and integration items ¹	(73)	-	
Tax and legal reserves ⁴	(124)	-	
Business development items ⁵	-	(9)	
Adjusted Marketing and Administrative Expenses	\$2,420	\$2,275	6%
% of Net Sales	22.2%	21.8%	0.4 pts
Research and Development Expenses	\$809	\$865	(6%)
Business optimization items ³	(18)	-	
Business development items ⁵	(25)	(113)	
Adjusted Research and Development Expenses	\$766	\$752	2%
% of Net Sales	7.0%	7.2%	(0.2 pts)
Other Expense (Income), Net	\$10	\$(133)	N/M
Gambro acquisition and integration items ¹	(10)	-	
Currency-related items ²	(62)	-	
Tax and legal reserves ⁴	35	-	
Reserve adjustments ⁶	-	91	
Adjusted Other Expense (Income), Net	\$(27)	\$(42)	N/M
Pre-Tax Income	\$2,118	\$2,315	(9%)
Impact of special items	273	14	
Adjusted Pre-Tax Income	\$2,391	\$2,329	3%
Income Tax Expense	\$432	\$483	(11%)
Impact of special items	84	30	
Adjusted Income Tax Expense	\$516	\$513	1%
% of Adjusted Pre-Tax Income	21.6%	22.0%	(0.4 pts)
Net Income	\$1,686	\$1,832	(8%)
Impact of special items	189	(16)	
Adjusted Net Income	\$1,875	\$1,816	3%
Diluted EPS	\$3.06	\$3.29	(7%)
Impact of special items	0.35	(0.02)	
Adjusted Diluted EPS	\$3.41	\$3.27	4%
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING			
Diluted	550	556	

¹ Cost of sales, marketing and administrative expenses and other expense (income), net in 2013 included total charges of \$98 million (\$78 million, or \$0.15 per diluted share, on an after-tax basis) principally related to the acquisition and integration of Gambro, including post-acquisition restructuring activities.

² Cost of sales and other expense (income), net in 2013 included a charge of \$11 million (\$7 million, or \$0.01 per diluted share, on an after-tax basis) related to the Venezuelan currency devaluation announced by the government of Venezuela in February 2013. Additionally, other expense (income), net in 2013 included a net loss of \$52 million (\$33 million, or \$0.06 per diluted share, on an after-tax basis) principally related to the company's derivative instruments used to hedge the anticipated foreign currency cash outflows for the Gambro acquisition.

³ Cost of sales in 2013 included a benefit of \$20 million (\$14 million, or \$0.03 per diluted share, on an after-tax basis) related to an adjustment to a previous business optimization reserve that is no longer probable of being utilized. R&D expenses in 2013 included charges of \$18 million (\$14 million, or \$0.03 per diluted share, on an after-tax basis) primarily related to contract termination costs associated with the discontinuation of the company's Alzheimer's disease program.

⁴ Marketing and administrative expenses in 2013 included charges totaling \$124 million (\$95 million, or \$0.17 per diluted share, on an after-tax basis) related to tax and legal reserves associated with VAT matters in Turkey and existing class-action and other related litigation, including litigation fees. Income tax expense in 2013 included a net benefit of \$6 million (\$0.01 per diluted share) related to uncertain tax positions in Switzerland and Turkey. Other expense (income), net in 2013 included the offsetting impact of \$35 million (\$0.06 per diluted share) in noncontrolling interest for the VAT and tax items above associated with the company's non-wholly owned subsidiary in Turkey.

⁵ R&D expenses in 2013 included an R&D charge of \$25 million (\$17 million, or \$0.03 per diluted share, on an after-tax basis) related to the company's collaboration agreement with JW Holdings. Cost of sales, marketing and administrative expenses and R&D expenses in 2012 included business development charges totaling \$128 million (\$102 million, or \$0.19 per diluted share, on an after-tax basis) which principally related to R&D charges of \$33 million associated with the company's global collaboration with Momenta Pharmaceuticals, Inc. (Momenta), \$30 million associated with the company's global collaboration with Chatham Therapeutics, LLC (Chatham), and \$50 million associated with the company's licensing agreement with Onconova.

⁶ Cost of sales in 2012 included a net benefit of \$23 million (\$27 million, or \$0.05 per diluted share, on an after-tax basis) primarily related to an adjustment to the COLLEAGUE infusion pump reserves as the company substantially completed its recall activities in the United States. Other expense (income), net in 2012 included a benefit of \$91 million, or \$0.16 per diluted share, consisting of gains of \$53 million and \$38 million for the reduction of certain contingent payment liabilities related to the prior acquisitions of Prism Pharmaceuticals, Inc. and ApaTech Limited, respectively, for which there was no tax expense recognized.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

BAXTER INTERNATIONAL INC.
Cash Flows from Operations and Changes in Net Debt
(unaudited)
(\$ in millions)

Cash Flows from Operations				
(Brackets denote cash outflows)				
	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2013	2012	2013	2012
Net income	\$544	\$583	\$1,686	\$1,832
Adjustments				
Depreciation and amortization	207	179	573	534
Deferred income taxes	148	78	85	197
Stock compensation	39	34	111	97
Realized excess tax benefits from stock issued under employee benefit plans	(13)	(6)	(32)	(14)
Other	(52)	37	2	(47)
Changes in balance sheet items				
Accounts and other current receivables, net	58	(42)	70	72
Inventories	(106)	(36)	(412)	(136)
Accounts payable and accrued liabilities	115	(53)	(56)	(282)
Business optimization and infusion pump payments	(29)	(63)	(81)	(226)
Other	55	36	169	134
Cash flows from operations	\$966	\$747	\$2,115	\$2,161
Changes in Net Debt				
Increase (decrease)				
	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2013	2012	2013	2012
Net debt, beginning of period ^A	\$3,046	\$2,961	\$2,660	\$2,290
Cash flows from operations	(966)	(747)	(2,115)	(2,161)
Capital expenditures	398	259	1,037	762
Dividends	267	184	757	558
Proceeds from stock issued under employee benefit plans	(114)	(121)	(436)	(293)
Purchases of treasury stock	146	105	863	1,065
Acquisitions and investments	3,685 ^B	116 ^B	3,772 ^B	585 ^B
Sales of investments and other investing activities	(4)	(12)	(14)	(86)
Payment of assumed Gambro debt	221	-	221	-
Other, including the effect of exchange rate changes	11	11	(55)	36
Increase (decrease) in net debt	3,644	(205)	4,030	466
Net debt, September 30 ^A	\$6,690	\$2,756	\$6,690	\$2,756
Key statistics, September 30:				
Days sales outstanding	59.4 ^C	57.0	59.4 ^C	57.0
Inventory turns	2.1	2.3	2.1	2.3

^A Net debt is a non-GAAP measure, refer to page 12 for a description of net debt and a reconciliation to GAAP measures.

^B Acquisitions and investments in 2013 included \$3.6 billion for the third quarter 2013 acquisition of Gambro (net of cash acquired) and \$51 million for the first quarter 2013 acquisition of the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. and Ipsen Pharma S.A.S. Acquisitions and investments in 2012 included \$100 million for the third quarter 2012 investment in Onconova preferred stock and execution of a licensing agreement, \$90 million for the second quarter 2012 exercise of the company's option to acquire the remaining equity interest in Sigma International General Medical Apparatus, LLC, \$25 million for the second quarter 2012 payment to execute the Chatham collaboration, \$304 million for the first quarter 2012 acquisition of Synovis Life Technologies, Inc., and \$33 million for the first quarter 2012 payment to execute the Momenta collaboration.

^C Includes the impact from the acquisition of Gambro in September 2013. Excluding Gambro, the company's days sales outstanding was 55.1 days as of September 30, 2013.

BAXTER INTERNATIONAL INC.
Total Debt to Net Debt Reconciliation
(unaudited)
(\$ in millions)

Total Debt to Net Debt Reconciliation ^A								
	September 30,	June 30,	March 31,	December 31,	September 30,	June 30,	March 31,	December 31,
	2013	2013	2013	2012	2012	2012	2012	2011
Short-term debt	\$42	\$33	\$333	\$27	\$16	\$385	\$313	\$256
Current maturities of long-term debt and lease obligations	372	378	377	323	317	497	485	190
Long-term debt and lease obligations	8,652	8,624	5,157	5,580	5,614	4,432	4,411	4,749
Total debt	9,066	9,035	5,867	5,930	\$5,947	5,314	5,209	5,195
Less: Cash and equivalents	(2,376)	(5,989)	(2,689)	(3,270)	(3,191)	(2,353)	(2,272)	(2,905)
Total net debt	\$6,690	\$3,046	\$3,178	\$2,660	\$2,756	\$2,961	\$2,937	\$2,290

^A Net debt represents the difference between total debt (defined as short-term debt, current maturities of long-term debt and lease obligations, and long-term debt and lease obligations as presented on the company's consolidated balance sheets) and cash and equivalents.

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.

BAXTER INTERNATIONAL INC.
Net Sales
Periods Ending September 30, 2013 and 2012
(unaudited)
(\$ in millions)

	Q3 2013	Q3 2012	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2013	YTD 2012	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
United States	\$831	\$790	5%	5%	\$2,386	\$2,262	5%	5%
International	789	732	8%	7%	2,402	2,288	5%	6%
Total BioScience	\$1,620	\$1,522	6%	6%	\$4,788	\$4,550	5%	6%
Medical Products								
United States	\$811	\$723	12%	12%	\$2,284	\$2,222	3%	3%
International	1,343	1,232	9%	10%	3,819	3,665	4%	5%
Total Medical Products¹	\$2,154	\$1,955	10%	11%	\$6,103	\$5,887	4%	4%
Baxter International Inc.								
United States	\$1,642	\$1,513	9%	9%	\$4,670	\$4,484	4%	4%
International	2,132	1,964	9%	9%	6,221	5,953	5%	5%
Total Baxter¹	\$3,774	\$3,477	9%	9%	\$10,891	\$10,437	4%	5%

¹ Includes net sales of \$100 million from Gambro following the acquisition in September 2013. Medical Products net sales excluding Gambro grew 5% at actual rates and 6% at constant rates during the third quarter of 2013, and grew 2% at both actual and constant rates during the first nine months of 2013. Total Baxter net sales excluding Gambro grew 6% at both actual and constant rates during the third quarter of 2013, and grew 3% at actual rates and 4% at constant rates during the first nine months of 2013.

BAXTER INTERNATIONAL INC.
Sales by Franchise ¹
Periods Ending September 30, 2013 and 2012
(unaudited)
(\$ in millions)

	Q3 2013	Q3 2012	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2013	YTD 2012	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Hemophilia ²	\$851	\$782	9%	9%	\$2,465	\$2,354	5%	6%
BioTherapeutics ³	532	516	3%	2%	1,554	1,498	4%	3%
BioSurgery ⁴	173	165	5%	5%	523	493	6%	6%
Vaccines ⁵	64	59	8%	5%	246	205	20%	22%
Total BioScience	\$1,620	\$1,522	6%	6%	\$4,788	\$4,550	5%	6%
Medical Products								
Fluid Systems ⁶	\$792	\$702	13%	13%	\$2,287	\$2,162	6%	6%
Renal ⁷	746	629	19%	21%	1,990	1,852	7%	9%
Specialty Pharmaceuticals ⁸	372	367	1%	1%	1,101	1,099	- %	- %
BioPharma Solutions ⁹	244	257	(5%)	(4%)	725	774	(6%)	(6%)
Total Medical Products	\$2,154	\$1,955	10%	11%	\$6,103	\$5,887	4%	4%
Total Baxter	\$3,774	\$3,477	9%	9%	\$10,891	\$10,437	4%	5%

¹ Effective January 1, 2013, Baxter has transitioned to a commercial franchise structure for reporting net sales. Prior period net sales have been reclassified to reflect the new commercial franchise structure. See Notes 2 - 9 below for a description of each commercial franchise.

² Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE) and plasma-derived hemophilia products (primarily FVII, FVIII and FEIBA). Recombinant and plasma-based products were previously reported separately.

³ Includes sales of the company's liquid formulation of the antibody-replacement therapy immunoglobulin product (GAMMAGARD LIQUID) and other plasma-based therapies such as albumin and alpha-1 antitrypsin products. Antibody therapies and plasma-based products were previously reported separately.

⁴ Consists of biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction and hard tissue regeneration, as well as soft tissue repair and microsurgery products.

⁵ Consists of vaccines for seasonal and pandemic influenza, as well as meningitis C and tick-borne encephalitis.

⁶ Principally includes IV therapies, infusion pumps, administration sets and premixed drugs platforms. IV therapies were previously reported with nutrition products in IV Therapies, and Infusion Systems and Global Injectables were previously reported separately.

⁷ Consists of PD and HD therapies, and includes net sales of \$100 million from Gambro following the acquisition in September 2013. Renal sales excluding Gambro grew 3% at actual rates and 5% at constant rates during the third quarter of 2013, and grew 2% at actual rates and 4% at constant rates during the first nine months of 2013.

⁸ Principally includes nutrition and anesthesia products. Nutrition products were previously reported with IV therapies in IV Therapies and anesthesia products were previously reported separately.

⁹ Principally includes sales from the pharmaceutical partnering business and pharmacy compounding services, which were previously reported with Global Injectables. Also includes revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the Transfusion Therapies business after the February 2007 divestiture.

BAXTER INTERNATIONAL INC.
Franchise Sales by U.S. and International¹
Three-Month Periods Ending September 30, 2013 and 2012
(unaudited)
(\$ in millions)

	Q3 2013			Q3 2012			% Growth		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
BioScience									
Hemophilia	\$350	\$501	\$851	\$346	\$436	\$782	1%	15%	9%
BioTherapeutics	374	158	532	347	169	516	8%	(7%)	3%
BioSurgery	100	73	173	97	68	165	3%	7%	5%
Vaccines	7	57	64	0	59	59	- %	(3%)	8%
Total BioScience	\$831	\$789	\$1,620	\$790	\$732	\$1,522	5%	8%	6%
Medical Products									
Fluid Systems	\$427	\$365	\$792	\$354	\$348	\$702	21%	5%	13%
Renal ²	130	616	746	100	529	629	30%	16%	19%
Specialty Pharmaceuticals	159	213	372	169	198	367	(6%)	8%	1%
BioPharma Solutions	95	149	244	100	157	257	(5%)	(5%)	(5%)
Total Medical Products ²	\$811	\$1,343	\$2,154	\$723	\$1,232	\$1,955	12%	9%	10%
Total Baxter ²	\$1,642	\$2,132	\$3,774	\$1,513	\$1,964	\$3,477	9%	9%	9%

¹ Effective January 1, 2013, Baxter has transitioned to a commercial franchise structure for reporting net sales. Prior period net sales have been reclassified to reflect the new commercial franchise structure. Refer to page 14 for additional details.

² Includes net sales of \$100 million from Gambro following the acquisition in September 2013. Renal sales excluding Gambro grew 3% at actual rates and 5% at constant rates during the third quarter of 2013. Medical Products net sales excluding Gambro grew 5% at actual rates and 6% at constant rates during the third quarter of 2013. Total Baxter net sales excluding Gambro grew 6% at both actual and constant rates during the third quarter of 2013.